Eplontersen
Identification
- Summary
Eplontersen is a transthyretin antisense oligonucleotide used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis.
- Brand Names
- Wainua
- Generic Name
- Eplontersen
- DrugBank Accession Number
- DB16199
- Background
Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery. It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis.2 Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in multiple organs, although wild-type misfolded TTR has also been observed to contribute to the disease pathophysiology.3 As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment.4
On December 21, 2023, the FDA approved eplontersen under the brand name WAINUA for the treatment of adult polyneuropathy of hereditary transthyretin-mediated amyloidosis. This approval was based on positive results demonstrated in the 35-week interim analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS+7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) Score were observed.6
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Gene Therapies
Antisense oligonucleotides - Synonyms
- Akcea ttr lrx
- AKCEA-TTR-LRx
- Eplontersen
- Ion-ttr-lrx
- Ionis-ttr-lrx
- External IDs
- ION-682884 FREE ACID
- ISIS-682884 FREE ACID
Pharmacology
- Indication
Eplontersen is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.5
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Polyneuropathies caused by hereditary transthyretin-mediated amyloidosis •••••••••••• ••••• ••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
In Study 1, following administration of the recommended eplontersen dosage every 4 weeks to patients with hATTR amyloidosis, a decrease in serum transthyretin (TTR) levels was observed at the first assessment and the (least square) mean serum TTR at Week 35 was reduced by 81% from baseline. Similar TTR reductions were observed across subgroups including Val30Met variant status, body weight, sex, age, or race. Eplontersen also reduced the mean steady-state serum vitamin A by 71% by Week 37.5
At a dose 2.7-times the maximum recommended dose for eplontersen, clinically significant QTc interval prolongation was not observed.5
- Mechanism of action
Eplontersen is an antisense oligonucleotide-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.5
Target Actions Organism ATransthyretin mRNA antisense oligonucleotideHumans - Absorption
The pharmacokinetic (PK) properties of WAINUA were evaluated following subcutaneous administration of single and multiple doses (once every 4 weeks) in healthy subjects and multiple doses (once every 4 weeks) in patients with hATTR amyloidosis. Eplontersen Cmax and AUC showed a slightly greater than dose-proportional increase following single subcutaneous doses ranging from 45 to 120 mg (i.e., 1- to 2.7- times the recommended dose) in healthy volunteers.5
Population estimates (mean ± SD) of steady-state maximum concentrations (Cmax), and area under the curve (AUCτ) were 283 ± 152 ng/mL, and 2190 ± 689 ng/mL, respectively, following 45 mg monthly dosing in patients with hATTR amyloidosis. No accumulation of eplontersen Cmax and AUC was observed in repeated dosing (once every 4 weeks).5
Following subcutaneous administration, eplontersen is absorbed with the time to maximum plasma concentrations of approximately 2 hours, based on population estimates.5
- Volume of distribution
Eplontersen is expected to distribute primarily to the liver and kidney cortex after subcutaneous dosing. The population estimate for the apparent central volume of distribution is 12 L and the apparent peripheral volume of distribution is 11,100 L.5
- Protein binding
Eplontersen is bound to human plasma proteins (>98%) in vitro.5
- Metabolism
Eplontersen is metabolized by endo- and exonucleases to short oligonucleotide fragments of varying sizes within the liver.5
- Route of elimination
The mean fraction of unchanged antisense oligonucleotide (ASO) eliminated in urine was less than 1% of the administered dose within 24 hours.5
- Half-life
The terminal elimination half-life is approximately 3 weeks.5
- Clearance
The clearance was estimated at 22.6 L/h based on the population pharmacokinetic model.1
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
There are no available data on WAINUA use in pregnant women to inform drug-associated risk of adverse developmental outcomes. Eplontersen treatment leads to a decrease in serum vitamin A levels and vitamin A supplementation is advised for patients taking eplontersen. Vitamin A is essential for normal embryofetal development; however, excessive vitamin A levels are associated with adverse developmental effects. The effect of vitamin A supplementation on the fetus in the setting of a reduction in maternal serum TTR caused by eplontersen administration is unknown.5
No adverse developmental effects were observed when eplontersen or a mouse-specific surrogate was administered to mice prior to mating and continuing throughout organogenesis.5
No dose adjustment is required in patients ≥65 years of age. In Study NCT04136184, 44 (31%) patients were 65 to 74 years of age, and 8 (5.6%) patients were ≥75 years of age. No overall differences in safety or effectiveness were observed between these patients and younger adult patients, but a greater sensitivity of some older individuals cannot be ruled out.5
Carcinogenicity studies have not been conducted with eplontersen.5
Eplontersen was negative for genotoxicity in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster lung cells) and in vivo (mouse bone marrow micronucleus) assays.5
Subcutaneous administration of eplontersen (0, 5, 25, or 75 mg/kg) or a mouse-specific surrogate (25 mg/kg) to male and female mice weekly prior to and during mating and continuing in females throughout the period of organogenesis resulted in no adverse effects on fertility.5
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Administer vitamin supplements. Inform patients that eplontersen treatment leads to a decrease in vitamin A levels, and supplementation of vitamin A at the recommended daily allowance is recommended.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Eplontersen sodium WSP2DHR2BD Not Available Not applicable - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Wainua Injection, solution 45 mg/45mg Subcutaneous AstraZeneca Pharmaceuticals LP 2023-12-21 Not applicable US
Categories
- ATC Codes
- N07XX21 — Eplontersen
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0GRZ0F5XJ6
- CAS number
- 1637600-16-8
References
- General References
- Diep JK, Yu RZ, Viney NJ, Schneider E, Guo S, Henry S, Monia B, Geary R, Wang Y: Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis. Br J Clin Pharmacol. 2022 Dec;88(12):5389-5398. doi: 10.1111/bcp.15468. Epub 2022 Aug 7. [Article]
- Coelho T, Waddington Cruz M, Chao CC, Parman Y, Wixner J, Weiler M, Barroso FA, Dasgupta NR, Jung SW, Schneider E, Viney NJ, Dyck PJB, Ando Y, Gillmore JD, Khella S, Gertz MA, Obici L, Berk JL: Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. Neurol Ther. 2023 Feb;12(1):267-287. doi: 10.1007/s40120-022-00414-z. Epub 2022 Dec 16. [Article]
- Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW, Yu RZ, Booten S, Murray H, Machemer T, Burel S, Murray S, Buchele G, Tsimikas S, Schneider E, Geary RS, Benson MD, Monia BP: Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 2021 Feb;8(1):652-661. doi: 10.1002/ehf2.13154. Epub 2020 Dec 7. [Article]
- Obici L, Mussinelli R: Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Neurotherapeutics. 2021 Oct;18(4):2286-2302. doi: 10.1007/s13311-021-01154-y. Epub 2021 Nov 30. [Article]
- FDA Approved Drug Products: WAINUA™ (eplontersen) injection, for subcutaneous use [Link]
- WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis [Link]
- External Links
- 2671939
- Wikipedia
- Eplontersen
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) 1 3 Completed Treatment Hereditary Transthyretin-Mediated Amyloid Polyneuropathy 1 3 Recruiting Treatment Hereditary Transthyretin-Mediated Amyloid Polyneuropathy 1 3 Recruiting Treatment Transthyretin (TTR) Amyloid Cardiomyopathy 1 3 Recruiting Treatment Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Subcutaneous 45 mg/45mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US8101743 No 2012-01-24 2025-04-01 US US10683499 No 2014-08-25 2034-08-25 US US9127276 No 2014-05-01 2034-05-01 US US9181549 No 2014-05-01 2034-05-01 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
References
- FDA Approved Drug Products: WAINUA™ (eplontersen) injection, for subcutaneous use [Link]
Drug created at December 15, 2020 18:15 / Updated at February 15, 2024 07:14